A unique role for IL-13 in inducing esophageal eosinophilia through MID-1 and STAT6

A unique role for IL-13 in inducing esophageal eosinophilia through MID-1 and STAT6 Jason L. N. Girkin Leon A. Sokulsky Malcolm R. Starkey Philip M. Hansbro Paul S. Foster Adam M. Collison Joerg Mattes Introduction

Eosinophilic esophagitis (EoE) is associated with allergen-driven inflammation of the esophagus and an upregulated Th2 cytokine signature. Recombinant interleukin (IL)-13 (rIL-13) administration to mice induces some of the hallmark features of EoE, including increased eotaxin expression and eosinophil recruitment. Inflammation in EoE has previously been shown to depend on the expression of TRAIL and MID-1, which reduced protein phosphatase 2A (PP2A) activity. The relationship between IL-13 and TRAIL signalling in esophageal eosinophilia is currently unknown.
Objective

To investigate the interaction between IL-13-driven eosinophil infiltration and TRAIL or MID-1 in the esophagus.
Method

We administered rIL-13 to wild type (WT), TRAIL-deficient ( Tnsf10 −/− ) or STAT6-deficient (STAT6 −/− ) mice and targeted MID-1 with small interfering RNA.
Results

rIL-13 administration to mice increased TRAIL and MID-1 expression in the esophagus while reducing PP2A activity. TRAIL deficient, but not STAT6 deficient mice demonstrated increased MID-1 expression and PP2A reduction upon IL-13 challenge which correlated with eosinophil infiltration into the esophagus. Silencing MID-1 expression with siRNA completely ablated IL-13 induced eosinophil infiltration of the esophagus, restored PP2A activity, and reduced eotaxin-1 expression.
Conclusion

IL-13-driven eosinophil infiltration of the esophagus induced eosinophilia and eotaxin-1 expression in a STAT6-dependent and MID-1-dependent manner. This study highlights a novel mechanism employed by IL-13 to perpetuate eosinophil infiltration.
11 6 2023 1248432 10.3389/falgy.2023.1248432 1 10.3389/crossmark-policy frontiersin.org true 1011153 & 1060074 1072000, 1079187 https://creativecommons.org/licenses/by/4.0/ 10.3389/falgy.2023.1248432 https://www.frontiersin.org/articles/10.3389/falgy.2023.1248432/full https://www.frontiersin.org/articles/10.3389/falgy.2023.1248432/full J Allergy Clin Immunol Liacouras 128 3 2011 Eosinophilic esophagitis: updated consensus recommendations for children and adults 10.1016/j.jaci.2011.02.040 J Allergy Clin Immunol DeBrosse 126 112 2010 Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982–1999 10.1016/j.jaci.2010.05.027 N Engl J Med Noel 351 940 2004 Eosinophilic esophagitis 10.1056/NEJM200408263510924 Gastroenterology Konikoff 131 1381 2006 A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis 10.1053/j.gastro.2006.08.033 Dig Dis Sci Abu-Sultaneh 56 97 2011 Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis 10.1007/s10620-010-1259-5 Clin Gastroenterol Hepatol Kagalwalla 4 1097 2006 Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis 10.1016/j.cgh.2006.05.026 Clin Exp Allergy Arias 46 78 2016 Dietary treatment modulates mast cell phenotype, density, and activity in adult eosinophilic oesophagitis 10.1111/cea.12504 Aliment Pharmacol Ther Arias 43 3 2016 Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies 10.1111/apt.13441 J Exp Med Foster 183 195 1996 Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model 10.1084/jem.183.1.195 Science Wills-Karp 282 2258 1998 Interleukin-13: central mediator of allergic asthma 10.1126/science.282.5397.2258 The health consequences of smoking: 50 years of progress: A report of the surgeon general 2014 J Clin Invest Mishra 107 83 2001 An etiological role for aeroallergens and eosinophils in experimental esophagitis 10.1172/JCI10224 Gastroenterology Mishra 125 1419 2003 Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism 10.1016/j.gastro.2003.07.007 Mucosal Immunol Blanchard 1 289 2008 Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses 10.1038/mi.2008.15 J Immunol Zuo 185 660 2010 IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway 10.4049/jimmunol.1000471 J Allergy Clin Immunol Collison 136 971 2015 TNF-related apoptosis-inducing ligand (TRAIL) regulates midline-1, thymic stromal lymphopoietin, inflammation, and remodeling in experimental eosinophilic esophagitis 10.1016/j.jaci.2015.03.031 Am J Physiol Gastrointest Liver Physiol Sokulsky 311 G998 2016 TRAIL Deficiency and PP2A activation with salmeterol ameliorates egg allergen driven eosinophilic esophagitis 10.1152/ajpgi.00151.2016 Nat Med Weckmann 13 1308 2007 Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease 10.1038/nm1660 Nat Med Collison 19 232 2013 The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity 10.1038/nm.3049 J Allergy Clin Immunol Rothenberg 150 1325 2022 Scientific journey to the first FDA-approved drug for eosinophilic esophagitis 10.1016/j.jaci.2022.09.027